Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Ruben A. Mesa, Claire Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary Frances McMullin, Jean‐Jacques Kiladjian, Lynda Foltz, Uwe Platzbecker, María Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew C. Perkins, Michael F. Leahy, Jun Kawashima, Sunhee Ro, Rafe Donahue, Boris Gorsh, Samineh Deheshi, Srđan Verstovšek
In: HemaSphere · 2023 · vol. 7(11) , pp. e966 · doi:10.1097/hs9.0000000000000966 · PMID:37901848 · W4387899802
article OA: gold CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

Abstract

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that typically manifests with debilitating symptoms that progressively worsen, negatively impacting patients' quality of life. Fatigue is a multifactorial and burdensome MF-related symptom due to its severity, persistence, and prevalence, with anemia a contributing factor and major unmet need. Clinical trials of the Janus kinase (JAK)1/JAK2/activin A receptor type 1 inhibitor momelotinib have shown consistent anemia benefits, in addition to improvements in MF-related symptoms. The phase 3 MOMENTUM trial in symptomatic and anemic patients met its primary end point, with a greater proportion having a Myelofibrosis Symptom Assessment Form (MFSAF) Total Symptom Score (TSS) reduction ≥50% at week 24 with momelotinib versus danazol. To support the positive primary end point result, we conducted longitudinal, responder, and time-to-event analyses of patient-reported outcomes from MOMENTUM, as measured by the MFSAF, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Patient-Reported Outcomes Measurement Information System (PROMIS) assessments. These analyses demonstrated rapid and durable response benefits with momelotinib, with achievement of first TSS response by day 29 and continued improvement over time. Improvements favored momelotinib versus danazol for each MFSAF individual item, and greater improvements were observed for disease- and cancer-related fatigue and physical functioning at week 24, with significant results for multiple items/domains across the 3 assessments. These findings are consistent in demonstrating that momelotinib provides substantial symptom benefit.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (29)

SciLite annotations

chemicals 89
momelotinib momelotinib danazol momelotinib momelotinib danazol momelotinib ruxolitinib ponatinib momelotinib iron momelotinib momelotinib momelotinib momelotinib ruxolitinib ruxolitinib ruxolitinib momelotinib ruxolitinib momelotinib danazol androgen danazol momelotinib danazol momelotinib momelotinib momelotinib danazol momelotinib danazol momelotinib danazol momelotinib danazol momelotinib danazol momelotinib danazol danazol momelotinib momelotinib danazol momelotinib danazol danazol danazol momelotinib momelotinib danazol momelotinib momelotinib momelotinib danazol danazol momelotinib danazol momelotinib momelotinib +29 more

Source provenance

openalex
last seen: 2026-05-11T04:07:12.765122+00:00
scilite
last seen: 2026-05-18T04:26:01.642840+00:00
License: CC0 · commercial use OK